Bacil Pharma share price
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹20.44.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 Oct 2026
- 1.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Oct 2026
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 14 Oct 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 5,940
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Sep 2026Filed 14 Oct
- Revenue
- ₹0.00 Cr
- Net profit
- ₹0.15 Cr
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
| ₹ crore | Dec 2024Filed 22 Jan | Mar 2025Filed 24 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 19 Dec | Dec 2025Filed 14 Feb | Mar 2026Filed 22 May | Jun 2026Filed 12 Aug | Sep 2026Filed 14 Oct |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | −0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | −0.02 | 0.15 |
The quarters either side of a change of basis do not compare. From the quarter to Sep 2026, the company reports a discontinued business.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
At or below today's level on 4% of 868 trading days over the last 5 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +12.3% | +62.2% | −30.8% | 0.0% |
| 3 years | +105.7% | – | – | 0.0% |
| 5 years | +72.6% | – | – | 0.0% |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Bacil Pharma in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Bacil Pharma is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Medi CapsMEDICAPQ | 31 | – | 0.3 | – | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Chandra Bhagat PharmaCBPL | 29 | 10.4 | 0.9 | – | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.0 | 2.0 | – | – | – | 28.9% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 7.0 | – | – | – | – | 22.4% | – | 0.00% |
 Gujarat Terce LaboratoriesGUJTERC | 27 | 12.7 | 2.7 | 7.6 | −7.2% | – | 25.8% | 25.8% | 0.00% |
 Lasa SupergenericsLASA | 25 | – | 0.5 | – | −95.2% | – | −24.8% | −24.8% | 0.00% |
 Walpar NutritionsWALPAR | 25 | 9.9 | 1.3 | – | +9.8% | −42.7% | 14.0% | – | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 22 | – | – | – | – | – | – | – | 0.00% |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
8 Oct · Management
5 Oct · Board meeting
Meeting on 14 Oct 2026: quarterly results
Sep 2026
Bacil Pharma share price by year
Each calendar year to 2025.Bacil Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 35.64 | −34.4% | 53.26 | 28.09 |
| 2024 | 54.34 | +751.7% | 62.56 | 6.50 |
| 2023 | 6.38 | −32.1% | 9.72 | 4.68 |
| 2022 | 9.40 | +31.5% | 9.55 | 3.67 |
| 2021 | 7.15 | +51.5% | 8.84 | 3.12 |
| 2020 | 4.72 | +137.2% | 6.01 | 1.57 |
| 2019 | 1.99 | −13.5% | 2.40 | 1.90 |
| 2018 | 2.30 | −61.6% | 5.70 | 2.30 |
| 2017 | 5.99 | −38.2% | 10.25 | 5.32 |
| 2016 | 9.70 | +79.0% | 10.18 | 3.32 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 21.34 | 21.34 | 19.42 | 19.98 | 20.00 | 5,940 |
| 22 Oct 2026 | 21.09 | 21.09 | 20.04 | 20.44 | 20.39 | 2,062 |
| 21 Oct 2026 | 19.83 | 21.29 | 19.33 | 21.09 | 19.39 | 22,102 |
| 19 Oct 2026 | 21.41 | 21.41 | 20.34 | 20.34 | 20.42 | 259 |
| 16 Oct 2026 | 20.86 | 21.95 | 20.86 | 21.41 | 20.96 | 1,204 |
| 15 Oct 2026 | 22.56 | 22.56 | 21.92 | 21.95 | 22.20 | 5,714 |
| 14 Oct 2026 | 24.48 | 24.48 | 22.98 | 23.02 | 23.06 | 9,052 |
| 13 Oct 2026 | 25.40 | 25.40 | 23.23 | 24.00 | 23.61 | 6,324 |
| 12 Oct 2026 | 24.79 | 24.80 | 23.54 | 24.45 | 23.83 | 16,752 |
| 9 Oct 2026 | 23.99 | 25.22 | 23.00 | 24.77 | 23.61 | 33,415 |
Company details
- Legal name
- Bacil Pharma Ltd.
- BSE code
- 524516
- ISIN
- INE711D01018
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 1994
- Face value
- ₹10
- CIN
- L24200MH1987PLC043427
- Corporate identity number, the registrar of companies' code for it